PlumX Metrics
Embed PlumX Metrics

Auriculocondylar Syndrome 2 results from dominant negative action of PLCB4 variants

DMM Disease Models and Mechanisms, ISSN: 1754-8411, Vol: 15, Issue: 4
2022
  • 8
    Citations
  • 82
    Usage
  • 6
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

Auriculocondylar Syndrome 2 (ARCND2) is a rare autosomal dominant craniofacial malformation syndrome linked to multiple genetic variants in the coding sequence of phospholipase C β4 (PLCB4). PLCB4 is a direct signaling effector of the Endothelin Receptor Type A (EDNRA)-Gq/11 pathway, which establishes the identity of neural crest cells (NCCs) that form lower jaw and middle ear structures. However, the functional consequences of PLCB4 variants on EDNRA signaling is not known. Here, we show using multiple signaling reporter assays that known PLCB4 variants resulting from missense mutations exert dominant negative interference on EDNRA signaling. In addition, using CRISPR/Cas9, we find that F0 mouse embryos modeling one PLCB4 variant have facial defects recapitulating those observed in hypomorphic Ednra mouse models, including a bone that we identify as an atavistic change in the posterior palate/oral cavity. Remarkably, we have identified a similar osseous phenotype in a child with ARCND2. Our results identify the disease mechanism of ARCND2, demonstrate that the PLCB4 variants cause craniofacial differences and illustrate how minor changes in signaling within NCCs may have driven evolutionary changes in jaw structure and function.

Bibliographic Details

Kanai, Stanley M; Heffner, Caleb; Cox, Timothy C; Cunningham, Michael L; Perez, Francisco A; Bauer, Aaron M; Reigan, Philip; Carter, Cristan; Murray, Stephen A; Clouthier, David E

The Company of Biologists

Neuroscience; Medicine; Immunology and Microbiology; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know